The global focal adhesion kinase market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The non-receptor tyrosine kinase focal adhesion kinase (FAK) provides signaling and scaffolding functions at integrin adhesion sites. It is involved in the management of the turnover of these adhesion sites, which is critical for cell migration control. FAK has been connected to cell defense against anoikis (suspension-induced cell death). FAK's ability to sequester receptor-interacting protein (RIP) from the death-receptor machinery can be linked to its anti-apoptotic action.

FAK is a non-receptor tyrosine kinase that initiates signal transduction pathways at integrin-mediated cell adhesion sites and through growth factor receptors. Survival, proliferation, migration, and invasion are all mechanisms involved in the formation and progression of cancer, and FAK is a crucial regulator of these activities. On a biochemical and functional level, FAK is connected to oncogenes. Furthermore, FAK overexpression and/or enhanced activity are found in a wide range of human malignancies, suggesting that FAK plays a role in carcinogenesis. FAK can be considered a possible target in the development of anti-cancer therapies owing to its crucial role in a variety of events associated with carcinogenesis, metastasis, and survival signaling. As a result, FAK inhibitors that are specific must be created. Combining these selective FAK inhibitors with cytotoxic drugs could be an extremely effective anti-cancer treatment. Therefore, the rising prevalence of cancer is driving the growth of the global focal adhesion kinase market during the forecast period. According to the Globocan 2020, there were nearly 19.3 million new cancer cases identified globally, with about 9.9 million cancer-related mortalities. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the global burden of cancer would be increased to 27.5 million new cancer cases and 16.3 million mortalities.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, and Teva Pharmaceutical Industries Ltd. among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Focal Adhesion Kinase Market Report by Segment

By Type 

• VS-4718
• CT-707
• GSK-2256098
• Cilengitide
• BI-853520
• Others 

By Application 

• Clinic
• Hospital
• Others

Global Focal Adhesion Kinase Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa